Does Tarceva really work?
A. Though individual results may vary, Tarceva has been shown to help some patients live longer. In a large clinical study, 23.8% of patients taking Tarceva (100mg) plus gemcitabine were living with their pancreatic cancer one year after they started this treatment, compared with 19.4% of patients receiving gemcitabine alone. That’s a 22.7% increase (approximately 23%) in one-year survival for patients on Tarceva plus gemcitabine therapy. How well Tarceva plus gemcitabine therapy works for you may differ from these results. Please speak with your doctor about whether Tarceva is right for you.